Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:56:59.684Z.
Calculation as of: 2026-10-06T18:56:59.684Z.
Quote observation: 2026-10-06T18:53:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
PE RATIO
N/A
Market Cap
$235.71M
PE Ratio
22.57
TTM Avg
18.71
3Y Avg
16.51
5Y Avg
18.62
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $238.81M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $237.36M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.39M | N/A | N/A | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.71M | 22.57 | 18.71 | 16.51 | 18.62 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.31M | N/A | 80.39 | 80.39 | 80.39 |
| Q32 Bio Inc. (QTTB)vs › | $242.58M | 2.92 | 4.27 | 4.27 | 3.78 |
| Galectin Therapeutics Inc. (GALT)vs › | $243.01M | N/A | 2.96 | 2.96 | 2.96 |
| SIGA Technologies, Inc. (SIGA)vs › | $234.61M | N/A | 10.01 | 8.82 | 11.38 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$16.27
Forward EPS (Est.)
$-1.38
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
